Publications
Publications
Show Results For
- All HBS Web
(1,032)
- Faculty Publications (260)
Drug
→
- April 2010
- Teaching Note
Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug (Brief Case)
By: John A. Quelch and Heather Beckham
Teaching Note to 4183 View Details
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
- December 2009 (Revised April 2010)
- Teaching Note
GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)
Teaching Note for [605074] and [605075]. View Details
- November 2009 (Revised March 2013)
- Case
PureCircle
By: David E. Bell and Aldo Sesia
In December 2008, the U.S. Food and Drug Administration (FDA) determined that high-purity Rebaudioside A (Reb A), a natural and calorie-free product that a young company named PureCircle manufactured from the Stevia plant, could be used in beverages, foods, and as a... View Details
- November 2009
- Case
The Explosion of Genetic Testing: Opportunities and Challenges
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
- July 2009 (Revised May 2010)
- Case
Pfizer: Letter from the Chairman (A)
By: Robert L. Simons and Natalie Kindred
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details
- April 2009 (Revised May 2010)
- Case
Partners In Health: HIV Care in Rwanda
By: Michael E. Porter, Scott S. Lee, Joseph Rhatigan and Jim Yong Kim
In 2005, Partners in Health (PIH) was invited by the Rwandan Ministry of Health to assume responsibility for the management of public health care in two rural districts in Eastern Rwanda and create an HIV treatment program at these sites. PIH successfully implemented a... View Details
- April 2009 (Revised November 2012)
- Case
Sermo, Inc.
By: Thomas R. Eisenmann and Lars Peter Christian Nielsen
Sermo operates the leading online professional network for physicians in the United States. Doctors use Sermo free of charge to post surveys regarding diagnostic and treatment concerns and to discuss these concerns, as well as challenges with managing their practices.... View Details
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details
- March 2008
- Case
The Multiple Sclerosis Center of Atlanta
By: Regina E. Herzlinger and Alfred Martin
The Multiple Sclerosis Center of Atlanta wishes to expand beyond Georgia. The factors influencing this decision are discussed, including drug treatments currently available, and the impact of future drugs in the FDA pipeline as well as financing issues. View Details
- March 2008
- Case
Novartis AG: Science-Based Business
By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
- 2008
- Case
Eli Lilly: Recreating Drug Discovery for the 21st Century
By: Rebecca Henderson and C. Reavis
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
- September 2007
- Article
Investigative Negotiation
By: Deepak Malhotra and Max H. Bazerman
This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into... View Details
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
- March 2007
- Teaching Note
Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)
Teaching note to 706454. View Details
- February 2007 (Revised April 2010)
- Case
Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics
By: Robert S. Huckman, Gary P. Pisano and Mark Rennella
Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression... View Details
- January 2007 (Revised January 2007)
- Background Note
Note on the U.S. Food and Drug Administration
By: Robert F. Higgins, Richard G. Hamermesh and Virginia Fuller
Describes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure. View Details